I have a hard time understanding why Starpharma has yet to begin commercializing Vivagel in the EU. They received commercial approval for the product 2 years ago yet they have not registered any sales there. I think the Starpharma management has taken the wrong approach in commercializing the product. They should have already begun commercializing the product in the EU (Germany/UK/France to start) as a test case to further raise awareness about the efficacy of the product within the global medical community. In doing so, they would have facilitated the successful commercial expansion of the product in other markets including rest of EU, USA. I think they have wasted a great opportunity to make the commercialization of the product a real success. Assuming they receive PMA approval from the FDA in the second half of 2018, how long will it take them to begin earning a significant amount of revenue from Vivagel? 2020?2021?2022?
- Forums
- ASX - By Stock
- SPL
- EU Sales Plans of Vivagel BV
EU Sales Plans of Vivagel BV
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.004(4.40%) |
Mkt cap ! $39.17M |
Open | High | Low | Value | Volume |
9.2¢ | 9.6¢ | 9.2¢ | $81.30K | 864.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28056 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 1285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28056 | 0.095 |
2 | 110498 | 0.094 |
1 | 26688 | 0.092 |
1 | 49413 | 0.091 |
4 | 122750 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 1285 | 1 |
0.100 | 112106 | 4 |
0.105 | 66531 | 3 |
0.110 | 16500 | 2 |
0.115 | 109827 | 3 |
Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |